A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

August 22, 2023

Study Completion Date

February 18, 2025

Conditions
Malignant MelanomaSquamous Cell Carcinoma of Skin
Interventions
DRUG

THOR-707

Solution for infusion: intravenous infusion

DRUG

Cemiplimab

Solution for infusion: intravenous infusion

Trial Locations (24)

2109

Investigational Site Number : 0360001, Macquarie University

10117

Investigational Site Number : 2760004, Berlin

20246

Investigational Site Number : 2760001, Hamburg

21079

Investigational Site Number : 2500002, Dijon

32429

Investigational Site Number : 2760006, Minden

39008

Investigational Site Number : 7240002, Santander

44093

Investigational Site Number : 2500001, Nantes

59037

Investigational Site Number : 2500005, Lille

68167

Investigational Site Number : 2760003, Mannheim

69495

Investigational Site Number : 2500006, Pierre-Bénite

80131

Investigational Site Number : 3800001, Napoli

80337

Investigational Site Number : 2760005, München

90211

Beverly Hills Cancer Center & Optima Diagnostic Imaging Site Number : 8400007, Beverly Hills

93009

Investigational Site Number : 2500003, Bobigny

1420000

Investigational Site Number : 1520006, Antofagasta

4800827

Investigational Site Number : 1520003, Temuco

7500921

Investigational Site Number : 1520002, Santiago

8241470

Investigational Site Number : 1520005, Santaigo

8420383

Investigational Site Number : 1520001, Santiago

Unknown

Investigational Site Number : 1520004, Santiago

06126

Investigational Site Number : 3800004, Perugia

08035

Investigational Site Number : 7240001, Barcelona

08036

Investigational Site Number : 7240004, Barcelona

08908

Investigational Site Number : 7240003, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT04913220 - A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | Biotech Hunter | Biotech Hunter